M. Ziemen
About
M. Ziemen is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Pharmacology.
According to data from OpenAlex, M. Ziemen has authored 32 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Surgery and 4 papers in Pharmacology. Recurrent topics in M. Ziemen's work include Diabetes Management and Research (20 papers), Diabetes Treatment and Management (17 papers) and Pancreatic function and diabetes (10 papers). M. Ziemen is often cited by papers focused on Diabetes Management and Research (20 papers), Diabetes Treatment and Management (17 papers) and Pancreatic function and diabetes (10 papers). M. Ziemen collaborates with scholars based in Germany, United States and United Kingdom. M. Ziemen's co-authors include Matthew C. Riddle, Hannele Yki‐Järvinen, Geremia B. Bolli, Isabel Muehlen-Bartmer, Richard M. Bergenstal, Philip Home, Marek Wardęcki, Emmanuelle Boëlle, Harmonie Goyeau and Maria Rojeski and has published in prestigious journals such as Diabetes Care, Journal of Antimicrobial Chemotherapy and Thrombosis and Haemostasis.
In The Last Decade
M. Ziemen
29 papers receiving 1.8k citations
Peers
M. Ziemen
Mona Hafez Egypt
W. Marg Germany
David E.R. Sutherland United States
Andrés Palacio Colombia
Joseph F. Largay United States
Aydın Tunçkale Türkiye
Cristóbal Morales Spain
J J Bending United Kingdom
L Hansen Denmark
Ferrán Rius Spain
Citations per year, relative to M. Ziemen M. Ziemen (= 1×)
peers
Mona Hafez
Countries citing papers authored by M. Ziemen
Since
Specialization
Citations
This map shows the geographic impact of M. Ziemen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Ziemen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Ziemen more than expected).
Fields of papers citing papers by M. Ziemen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by M. Ziemen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Ziemen. The network helps show where M. Ziemen may publish in the future.
Co-authorship network of co-authors of M. Ziemen
This figure shows the co-authorship network connecting the top 25 collaborators of M. Ziemen. A scholar is included among the top collaborators of M. Ziemen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Ziemen. M. Ziemen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Home, Philip, et al.. (2018). Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes. Diabetes Technology & Therapeutics. 20(2). 160–170.
2.
Home, Philip, Richard M. Bergenstal, Geremia B. Bolli, et al.. (2017). Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes ( EDITION 4). Diabetes Obesity and Metabolism. 20(1). 121–128.
3.
Riddle, Matthew C., Geremia B. Bolli, Philip Home, et al.. (2016). Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. Diabetes Technology & Therapeutics. 18(4). 252–257.
4.
Home, Philip, Richard M. Bergenstal, Geremia B. Bolli, et al.. (2015). New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 38(12). 2217–2225.
5.
Riddle, Matthew C., Hannele Yki‐Järvinen, Geremia B. Bolli, et al.. (2015). One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension. Diabetes Obesity and Metabolism. 17(9). 835–842.
6.
Yki-Järvinen, H, Richard M. Bergenstal, Geremia B. Bolli, et al.. (2015). Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension. Diabetes Obesity and Metabolism. 17(12). 1142–1149.
7.
Bolli, Geremia B., Matthew C. Riddle, Richard M. Bergenstal, et al.. (2015). New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naïve people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obesity and Metabolism. 17(4). 386–394.
8.
Yki‐Järvinen, Hannele, Richard M. Bergenstal, M. Ziemen, et al.. (2014). New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2). Diabetes Care. 37(12). 3235–3243.
9.
Rabasa‐Lhoret, Rémi, Matthew C. Riddle, Geremia B. Bolli, et al.. (2014). New Insulin Glargine 300 U/mL: Efficacy and Safety of Adaptable vs. Fixed Dosing Intervals in People with T2DM. Canadian Journal of Diabetes. 38(5). S53–S53.
10.
Leiter, Lawrence A., Matthew C. Riddle, Geremia B. Bolli, et al.. (2014). Sustained Glycemic Control and Less Hypoglycemia with New Insulin Glargine 300 U/mL Compared with 100 U/mL: 1-Year Results in People with T2DM Using Basal + Mealtime Insulin (EDITION 1). Canadian Journal of Diabetes. 38(5). S8–S9.
11.
Riddle, Matthew C., et al.. (2014). New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). Diabetes Care. 37(10). 2755–2762.
12.
Riddle, Matthew C., et al.. (2013). An investigational new insulin glargine U300: glucose control and hypoglycaemia in people with type 2 diabetes using basal and mealtime Insulin (EDITION I).
13.
Benedetti, M. Massi, et al.. (2003). A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 Diabetes. Hormone and Metabolic Research. 35(3). 189–196.
14.
Yki‐Järvinen, Hannele, et al.. (2000). Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.. Diabetes Care. 23(8). 1130–1136.
15.
Schäfer, Volker, et al.. (1992). In-vitro activity of cefpirome against isolates from patients with urinary tract, lower respiratory tract and wound infections. Journal of Antimicrobial Chemotherapy. 29(suppl A). 7–12.
16.
Shah, P. M., et al.. (1992). Comparison of clinical response to cefpirome treatment and minimum inhibitory concentration of causative isolates. Journal of Antimicrobial Chemotherapy. 29(suppl A). 75–80.
17.
Ziemen, M., et al.. (1988). Haemostasis during treatment with ciprofloxacin. Infection. 16(S1). S65–S68.
18.
Althoff, P.-H., C. Rosak, W. Weichert, et al.. (1987). Spontaneous platelet aggregation and coagulation parameters as risk factors for arterial occlusions in diabetics. Results of the PARD-study.. PubMed. 5(3). 181–95.
19.
Althoff, P.-H., C. Rosak, W. Weichert, et al.. (1986). Haemostasiological parameters as risk factor for new arterial occlusions in diabetics.. PubMed. 64(20). 1042–6.
20.
Ziemen, M.. (1984). Thrombozytenfunktion und plasmatische Gerinnung nach Intoxikation mit Organophosphaten. Journal of Molecular Medicine. 62(17). 814–820.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mona Hafez Breakdown of academic impact, for papers by W. Marg Breakdown of academic impact, for papers by David E.R. Sutherland Breakdown of academic impact, for papers by Andrés Palacio Breakdown of academic impact, for papers by Joseph F. Largay Breakdown of academic impact, for papers by Aydın Tunçkale Breakdown of academic impact, for papers by Cristóbal Morales Breakdown of academic impact, for papers by J J Bending Breakdown of academic impact, for papers by L Hansen Breakdown of academic impact, for papers by Ferrán Rius